Orthofix Med Inc Financials
Orthofix Med Inc (OFIX) reported $822.3M in revenue for fiscal year 2025, up 2.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gross profit expansion is being mostly consumed by heavy operating overhead, leaving Orthofix near cash breakeven but unprofitable.
From FY2023 to FY2025, operating cash flow moved from-$45.8M to$33.3M , a much bigger repair than the income statement alone suggests. Yet net income was still-$92.2M and free cash flow was-$1.3M in FY2025, showing the loss now reflects more non-cash expense and leaner inventory than outright cash burn.
FY2025 gross margin reached
The company still has near-term liquidity, with a current ratio of 2.4x and cash of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Orthofix Med Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Orthofix Med Inc has an operating margin of -9.9%, meaning the company loses $10 on every $100 of revenue. This results in a profitability score of 28/100. This is up from -10.6% the prior year.
Orthofix Med Inc's revenue grew a modest 2.9% year-over-year to $822.3M. This slow but positive growth earns a score of 50/100.
Orthofix Med Inc carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.45, Orthofix Med Inc holds $2.45 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 68/100.
While Orthofix Med Inc generated $33.3M in operating cash flow, capex of $34.6M consumed most of it, leaving -$1.3M in free cash flow. This results in a low score of 22/100, reflecting heavy capital investment rather than weak cash generation.
Orthofix Med Inc posts a -20.5% return on equity (ROE), meaning it loses $20 for every $100 of shareholders' equity. This results in a returns score of 27/100. This is up from -25.0% the prior year.
Orthofix Med Inc scores 1.00, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($407.7M) relative to total liabilities ($400.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Orthofix Med Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Orthofix Med Inc reported a net loss of $92.2M while generating $33.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Orthofix Med Inc reported an operating loss of $81.4M against $17.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Orthofix Med Inc generated $822.3M in revenue in fiscal year 2025. This represents an increase of 2.9% from the prior year.
Orthofix Med Inc's EBITDA was -$4.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 83.3% from the prior year.
Orthofix Med Inc reported -$92.2M in net income in fiscal year 2025. This represents an increase of 26.8% from the prior year.
Orthofix Med Inc earned -$2.33 per diluted share (EPS) in fiscal year 2025. This represents an increase of 29.4% from the prior year.
Cash & Balance Sheet
Orthofix Med Inc recorded an outflow of $1.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 85.9% from the prior year.
Orthofix Med Inc held $82.0M in cash against $157.4M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Orthofix Med Inc's gross margin was 68.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.
Orthofix Med Inc's operating margin was -9.9% in fiscal year 2025, reflecting core business profitability. This is up 0.7 percentage points from the prior year.
Orthofix Med Inc's net profit margin was -11.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.5 percentage points from the prior year.
Orthofix Med Inc's ROE was -20.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.6 percentage points from the prior year.
Capital Allocation
Orthofix Med Inc invested $65.8M in research and development in fiscal year 2025. This represents a decrease of 10.6% from the prior year.
Orthofix Med Inc invested $34.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.7% from the prior year.
Not reported for fiscal year 2025.
OFIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $833.2M | $822.3M+2.9% | $799.5M+7.1% | $746.6M+62.1% | $460.7M-0.8% | $464.5M+14.2% | $406.6M-11.6% | $460.0M+1.5% | $453.0M+4.4% | $433.8M+5.9% | $409.8M+3.4% | $396.5M-1.4% | $402.3M+1.2% | $397.6M-9.7% | $440.2M+1.1% | $435.5M |
| Cost of Revenue | $239.1M | $256.3M+1.1% | $253.6M-2.6% | $260.4M+110.7% | $123.5M+7.5% | $114.9M+12.8% | $101.9M+1.3% | $100.6M+4.1% | $96.6M+3.9% | $93.0M+5.9% | $87.9M+1.5% | $86.5M-12.5% | $98.9M-7.5% | $106.9M+6.1% | $100.7M+4.5% | $96.4M |
| Gross Profit | $594.1M | $566.0M+3.7% | $545.9M+12.3% | $486.3M+44.2% | $337.2M-3.5% | $349.6M+14.7% | $304.7M-15.2% | $359.3M+0.8% | $356.4M+4.6% | $340.8M+5.9% | $321.9M+3.9% | $310.0M+2.2% | $303.4M+4.4% | $290.7M-14.4% | $339.5M+0.1% | $339.1M |
| R&D Expenses | $61.4M | $65.8M-10.6% | $73.6M-8.2% | $80.2M+63.5% | $49.1M-1.1% | $49.6M+27.1% | $39.1M+12.8% | $34.6M+4.3% | $33.2M+11.8% | $29.7M+3.1% | $28.8M+9.1% | $26.4M+5.6% | $25.0M-6.6% | $26.8M-6.3% | $28.6M+25.0% | $22.9M |
| SG&A Expenses | $557.8M | $554.3M+4.1% | $532.5M+0.4% | $530.4M+71.8% | $308.8M+345.2% | $69.4M+2.1% | $67.9M-20.6% | $85.6M+2.8% | $83.3M+15.8% | $71.9M-5.9% | $76.4M-12.3% | $87.2M+10.2% | $79.1M+17.1% | $67.5M+25.8% | $53.6M-17.2% | $64.8M |
| Operating Income | -$39.1M | -$81.4M+3.8% | -$84.6M+39.2% | -$139.1M-948.5% | -$13.3M-59.6% | -$8.3M-32.7% | -$6.3M+66.6% | -$18.8M-162.4% | $30.1M-26.3% | $40.8M+93.7% | $21.1M+127.6% | $9.3M-46.0% | $17.1M+253.1% | -$11.2M-114.9% | $74.9M+1032.5% | $6.6M |
| Interest Expense | -$20.8M | -$17.5M+41.0% | -$29.6M-243.3% | -$8.6M-570.1% | -$1.3M+29.9% | -$1.8M+26.0% | -$2.5M-1935.2% | -$122K+85.3% | -$828K-99.0% | -$416K-154.5% | $763K+256.0% | -$489K-127.4% | $1.8M-2.3% | $1.8M-56.1% | $4.2M-23.5% | $5.4M |
| Income Tax | $1.4M | $1.4M-34.9% | $2.1M-21.9% | $2.7M+32.9% | $2.0M-91.8% | $24.9M+962.5% | -$2.9M-304.2% | $1.4M-84.4% | $9.1M-68.8% | $29.1M+87.4% | $15.5M+43.1% | $10.8M-33.0% | $16.2M+113.1% | $7.6M-68.3% | $23.9M+65.8% | $14.4M |
| Net Income | -$61.7M | -$92.2M+26.8% | -$126.0M+16.8% | -$151.4M-666.6% | -$19.8M+48.5% | -$38.4M-1624.8% | $2.5M+108.8% | -$28.5M-306.1% | $13.8M+121.9% | $6.2M+103.6% | $3.1M+208.8% | -$2.8M+67.1% | -$8.5M+70.4% | -$28.8M-167.2% | $42.9M+342.1% | -$17.7M |
| EPS (Diluted) | — | -$2.33+29.4% | -$3.30+19.9% | -$4.12 | -$0.98+49.7% | -$1.95-1600.0% | $0.13+108.6% | -$1.51-309.7% | $0.72+111.8% | $0.34+100.0% | $0.17+213.3% | -$0.15+67.4% | -$0.46+70.1% | -$1.54-169.7% | $2.21+327.8% | -$0.97 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OFIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $850.6M-4.8% | $893.3M-3.5% | $925.3M+101.8% | $458.6M-3.8% | $476.6M-9.4% | $525.9M+6.1% | $495.6M+6.2% | $466.6M+15.1% | $405.4M+8.9% | $372.1M-7.0% | $400.2M+1.8% | $393.0M-4.6% | $412.0M-11.3% | $464.5M-32.2% | $685.4M |
| Current Assets | $416.8M-3.8% | $433.3M+3.1% | $420.4M+64.2% | $256.0M-5.0% | $269.5M-0.3% | $270.4M+3.8% | $260.6M+6.5% | $244.6M-2.8% | $251.8M+29.5% | $194.4M-8.4% | $212.3M-3.1% | $219.0M-17.4% | $265.1M-11.8% | $300.6M-43.4% | $531.1M |
| Cash & Equivalents | $82.0M-1.5% | $83.2M+151.4% | $33.1M-34.7% | $50.7M-42.3% | $87.8M-8.8% | $96.3M+38.1% | $69.7M+0.1% | $69.6M-14.2% | $81.2M+105.1% | $39.6M-37.8% | $63.7M+72.9% | $36.8M+27.3% | $28.9M-6.0% | $30.8M-6.0% | $32.7M |
| Inventory | $172.3M-9.0% | $189.5M-14.7% | $222.2M+121.8% | $100.2M+20.7% | $83.0M-2.0% | $84.6M+2.7% | $82.4M+7.2% | $76.8M-5.5% | $81.3M+28.4% | $63.3M+10.0% | $57.6M-3.8% | $59.8M-17.7% | $72.7M+4.1% | $69.8M-14.4% | $81.5M |
| Accounts Receivable | $135.7M+0.8% | $134.7M+5.2% | $128.1M+54.6% | $82.9M+5.5% | $78.6M+8.5% | $72.4M-16.6% | $86.8M+11.7% | $77.7M+22.6% | $63.4M+9.7% | $57.8M-3.3% | $59.8M-2.5% | $61.4M-13.3% | $70.8M-31.8% | $103.8M+3.9% | $99.9M |
| Goodwill | $194.9M0.0% | $194.9M0.0% | $194.9M+173.3% | $71.3M0.0% | $71.3M-15.1% | $84.0M+18.0% | $71.2M-1.7% | $72.4M+35.2% | $53.6M0.0% | $53.6M0.0% | $53.6M0.0% | $53.6M0.0% | $53.6M-28.0% | $74.4M+1.8% | $73.1M |
| Total Liabilities | $400.6M+2.7% | $390.2M+19.5% | $326.6M+168.2% | $121.8M-12.8% | $139.7M-17.3% | $169.0M+0.6% | $168.0M+28.0% | $131.2M+20.7% | $108.7M+0.1% | $108.6M-1.2% | $109.9M+17.8% | $93.3M-19.6% | $116.1M+7.4% | $108.1M-72.5% | $393.3M |
| Current Liabilities | $170.5M+1.1% | $168.6M+2.1% | $165.2M+97.6% | $83.6M-21.0% | $105.8M+1.9% | $103.9M+22.4% | $84.9M-1.2% | $85.9M+8.2% | $79.4M-4.8% | $83.4M+1.8% | $82.0M+23.4% | $66.4M-5.6% | $70.3M+7.7% | $65.3M-64.4% | $183.7M |
| Long-Term Debt | $157.4M+0.2% | $157.0M+68.6% | $93.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Total Equity | $450.0M-10.6% | $503.1M-16.0% | $598.7M+77.7% | $336.9M0.0% | $336.9M-5.6% | $356.9M+8.9% | $327.6M-2.3% | $335.4M+13.1% | $296.6M+12.6% | $263.5M-9.2% | $290.3M-3.1% | $299.6M+1.3% | $295.9M-17.0% | $356.4M+27.2% | $280.3M |
| Retained Earnings | -$368.3M-33.4% | -$276.1M-83.9% | -$150.1M-12101.9% | $1.3M-94.0% | $21.0M-64.6% | $59.4M+2.8% | $57.7M-33.7% | $87.1M+23.7% | $70.4M+9.7% | $64.2M+2.6% | $62.6M-4.3% | $65.4M-11.6% | $73.9M-28.1% | $102.7M+42.6% | $72.0M |
OFIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $16.3M | $33.3M+29.3% | $25.8M+156.4% | -$45.8M-296.5% | -$11.5M-162.5% | $18.5M-75.1% | $74.3M+131.9% | $32.0M-35.8% | $49.9M+28.1% | $39.0M-34.0% | $59.1M+35.5% | $43.6M-14.8% | $51.2M-23.7% | $67.0M+559.7% | $10.2M-84.3% | $64.7M |
| Capital Expenditures | $44.1M | $34.6M-0.7% | $34.9M-42.1% | $60.3M+182.0% | $21.4M+20.1% | $17.8M+14.9% | $15.5M-18.5% | $19.0M+39.8% | $13.6M-7.3% | $14.7M-10.8% | $16.4M-39.6% | $27.2M+50.5% | $18.1M-27.1% | $24.8M-11.5% | $28.0M+12.1% | $25.0M |
| Free Cash Flow | -$27.8M | -$1.3M+85.9% | -$9.1M+91.4% | -$106.0M-222.2% | -$32.9M-4868.4% | $690K-98.8% | $58.8M+351.0% | $13.0M-64.1% | $36.3M+49.4% | $24.3M-43.0% | $42.6M+159.8% | $16.4M-50.4% | $33.1M-21.7% | $42.3M+337.0% | -$17.8M-144.8% | $39.8M |
| Investing Cash Flow | -$43.9M | -$34.6M-25.4% | -$27.6M+16.8% | -$33.1M-35.0% | -$24.5M-6.6% | -$23.0M+56.0% | -$52.3M-128.3% | -$22.9M+62.4% | -$61.0M-270.3% | -$16.5M+24.9% | -$21.9M+42.8% | -$38.3M-92.2% | -$19.9M+35.8% | -$31.1M | N/A | -$31.0M |
| Financing Cash Flow | $63.6M | -$786K-101.6% | $50.7M-22.4% | $65.3M+83846.2% | -$78K+97.8% | -$3.6M-211.6% | $3.2M+130.4% | -$10.7M-457.1% | $3.0M-15.4% | $3.5M+107.7% | -$46.1M-286.5% | $24.7M+222.4% | -$20.2M+47.3% | -$38.4M | N/A | -$13.7M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $63.4M+447.9% | $11.6M | N/A | $39.5M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OFIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.8%+0.6pp | 68.3%+3.1pp | 65.1%-8.1pp | 73.2%-2.1pp | 75.3%+0.3pp | 74.9%-3.2pp | 78.1%-0.5pp | 78.7%+0.1pp | 78.5%0.0pp | 78.6%+0.4pp | 78.2%+2.8pp | 75.4%+2.3pp | 73.1%-4.0pp | 77.1%-0.7pp | 77.9% |
| Operating Margin | -9.9%+0.7pp | -10.6%+8.0pp | -18.6%-15.8pp | -2.9%-1.1pp | -1.8%-0.2pp | -1.5%+2.5pp | -4.1%-10.7pp | 6.6%-2.8pp | 9.4%+4.3pp | 5.1%+2.8pp | 2.3%-1.9pp | 4.3%+7.1pp | -2.8%-19.8pp | 17.0%+15.5pp | 1.5% |
| Net Margin | -11.2%+4.5pp | -15.8%+4.5pp | -20.3%-16.0pp | -4.3%+4.0pp | -8.3%-8.9pp | 0.6%+6.8pp | -6.2%-9.2pp | 3.0%+1.6pp | 1.4%+0.7pp | 0.8%+1.5pp | -0.7%+1.4pp | -2.1%+5.1pp | -7.2%-17.0pp | 9.7%+13.8pp | -4.1% |
| Return on Equity | -20.5%+4.6pp | -25.0%+0.3pp | -25.3%-19.4pp | -5.9%+5.5pp | -11.4%-12.1pp | 0.7%+9.4pp | -8.7%-12.8pp | 4.1%+2.0pp | 2.1%+0.9pp | 1.2%+2.1pp | -1.0%+1.9pp | -2.9%+6.9pp | -9.7%-21.8pp | 12.0%+18.3pp | -6.3% |
| Return on Assets | -10.8%+3.3pp | -14.1%+2.2pp | -16.4%-12.0pp | -4.3%+3.7pp | -8.1%-8.5pp | 0.5%+6.2pp | -5.7%-8.7pp | 3.0%+1.4pp | 1.5%+0.7pp | 0.8%+1.5pp | -0.7%+1.5pp | -2.2%+4.8pp | -7.0%-16.2pp | 9.2%+11.8pp | -2.6% |
| Current Ratio | 2.45-0.1x | 2.570.0x | 2.54-0.5x | 3.06+0.5x | 2.55-0.1x | 2.60-0.5x | 3.07+0.2x | 2.85-0.3x | 3.17+0.8x | 2.33-0.3x | 2.59-0.7x | 3.30-0.5x | 3.77-0.8x | 4.60+1.7x | 2.89 |
| Debt-to-Equity | 0.350.0x | 0.31+0.2x | 0.16-0.2x | 0.36-0.1x | 0.41-0.1x | 0.470.0x | 0.51+0.1x | 0.390.0x | 0.370.0x | 0.410.0x | 0.38+0.4x | 0.00-0.4x | 0.39+0.1x | 0.30-1.1x | 1.40 |
| FCF Margin | -0.2%+1.0pp | -1.1%+13.1pp | -14.2%-7.1pp | -7.1%-7.3pp | 0.1%-14.3pp | 14.5%+11.6pp | 2.8%-5.2pp | 8.0%+2.4pp | 5.6%-4.8pp | 10.4%+6.3pp | 4.1%-4.1pp | 8.2%-2.4pp | 10.6%+14.7pp | -4.0%-13.2pp | 9.1% |
Similar Companies
Where Orthofix Med Inc Ranks
Frequently Asked Questions
What is Orthofix Med Inc's annual revenue?
Orthofix Med Inc (OFIX) reported $822.3M in total revenue for fiscal year 2025. This represents a 2.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Orthofix Med Inc's revenue growing?
Orthofix Med Inc (OFIX) revenue grew by 2.9% year-over-year, from $799.5M to $822.3M in fiscal year 2025.
Is Orthofix Med Inc profitable?
No, Orthofix Med Inc (OFIX) reported a net income of -$92.2M in fiscal year 2025, with a net profit margin of -11.2%.
What is Orthofix Med Inc's EBITDA?
Orthofix Med Inc (OFIX) had EBITDA of -$4.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Orthofix Med Inc have?
As of fiscal year 2025, Orthofix Med Inc (OFIX) had $82.0M in cash and equivalents against $157.4M in long-term debt.
What is Orthofix Med Inc's gross margin?
Orthofix Med Inc (OFIX) had a gross margin of 68.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Orthofix Med Inc's operating margin?
Orthofix Med Inc (OFIX) had an operating margin of -9.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Orthofix Med Inc's net profit margin?
Orthofix Med Inc (OFIX) had a net profit margin of -11.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Orthofix Med Inc's return on equity (ROE)?
Orthofix Med Inc (OFIX) has a return on equity of -20.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Orthofix Med Inc's free cash flow?
Orthofix Med Inc (OFIX) recorded an outflow of $1.3M in free cash flow during fiscal year 2025. This represents a 85.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Orthofix Med Inc's operating cash flow?
Orthofix Med Inc (OFIX) generated $33.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Orthofix Med Inc's total assets?
Orthofix Med Inc (OFIX) had $850.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Orthofix Med Inc's capital expenditures?
Orthofix Med Inc (OFIX) invested $34.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Orthofix Med Inc spend on research and development?
Orthofix Med Inc (OFIX) invested $65.8M in research and development during fiscal year 2025.
What is Orthofix Med Inc's current ratio?
Orthofix Med Inc (OFIX) had a current ratio of 2.45 as of fiscal year 2025, which is generally considered healthy.
What is Orthofix Med Inc's debt-to-equity ratio?
Orthofix Med Inc (OFIX) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Orthofix Med Inc's return on assets (ROA)?
Orthofix Med Inc (OFIX) had a return on assets of -10.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Orthofix Med Inc's Altman Z-Score?
Orthofix Med Inc (OFIX) has an Altman Z-Score of 1.00, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Orthofix Med Inc's Piotroski F-Score?
Orthofix Med Inc (OFIX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Orthofix Med Inc's earnings high quality?
Orthofix Med Inc (OFIX) reported a net loss of $92.2M while generating $33.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Orthofix Med Inc cover its interest payments?
Orthofix Med Inc (OFIX) reported an operating loss of $81.4M against $17.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Orthofix Med Inc?
Orthofix Med Inc (OFIX) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.